公开(公告)号：US20150133515A1

公开(公告)日：2015-05-14

申请号：US14534993

申请日：2014-11-06

Applicant: STC.UNM

Inventor： ALEXANDRE CHIGAEV ,  LARRY A. SKLAR

IPC: G01N33/50 ,  A61K31/42 ,  A61K31/357 ,  A61K31/197

CPC classification number: G01N33/5041 ,  A61K31/195 ,  A61K31/197 ,  A61K31/357 ,  A61K31/36 ,  A61K31/42 ,  G01N33/5055 ,  G01N33/68 ,  G01N2333/70546 ,  G01N2333/7055 ,  G01N2500/04 ,  G01N2500/10

Abstract: This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery based upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.

Abstract translation: 本发明一般涉及整联蛋白配体发现和基于诱导配体诱导表位的整联蛋白配体发现的方法。 这样的配体具有作为抗炎，抗血管生成和/或抗血栓形成剂的活性剂的潜力，并且用于治疗整联蛋白介导的疾病和/或病症。

公开(公告)号：US20150087886A1

公开(公告)日：2015-03-26

申请号：US14510476

申请日：2014-10-09

Applicant: STC.UNM

Inventor： Robert Hromas ,  Andrei Leitao ,  Tudor I. Oprea ,  Larry A. Sklar ,  Elizabeth A. Williamson ,  Justin Wray ,  Wei Wang

IPC: C07D215/56 ,  C07D401/06 ,  A61K31/475 ,  A61N5/10 ,  C07D401/12 ,  A61K45/06 ,  C07D401/10 ,  A61K31/7048 ,  A61K31/47 ,  A61K31/496

CPC classification number: C07D215/56 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/475 ,  A61K31/496 ,  A61K31/7048 ,  A61K45/06 ,  A61N5/1001 ,  A61N5/1045 ,  A61N2005/1087 ,  A61N2005/1098 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  A61K2300/00

Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-1) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy.In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP-16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy.

Abstract translation: 本发明涉及新的癌症治疗组合物和相关的治疗方法。 更具体地说，本发明部分涉及同时损伤DNA的DNA复制和修复蛋白质Metnase和/或Intnase（也称为Gypsy整合酶，Gypsy Integrease-1，Gypsy Retransposon Integrase 1或GIN-1）的小型化学双功能抑制剂， 以及利用抑制剂增加包括放射治疗在内的癌症治疗方案的有效性的治疗方法。 在优选的实施方案中，本发明的化合物，组合物和治疗方法用于治疗患有白血病的患者（例如急性骨髓性白血病（AML）和相关的癌症）。在这些治疗的某些方面，化合物，组合物和治疗方法 本发明作为单一疗法（在某些情况下，对已显示出对Topo IIalpha抑制剂如VP-16具有抗性的患者）施用，或者与本文另有描述的Topo IIal抑制剂或其它抗癌剂共同施用，或 结合放射治疗。

公开(公告)号：US20140165021A1

公开(公告)日：2014-06-12

申请号：US14069822

申请日：2013-11-01

Applicant: STC.UNM

Inventor： Marios Stephanou Pattichis ,  Yuebing Jiang ,  Daniel Rolando Llamocca Obregon

IPC: G06F17/50

CPC classification number: G06F9/4401 ,  G06F17/5054 ,  G06F2217/08 ,  H03H17/0241 ,  H03H17/0294 ,  H03H17/06 ,  H04N19/625

Abstract: A dynamically reconfigurable framework manages processing applications in order to meet time-varying constraints to select an optimal hardware architecture. The optimal architecture satisfies time-varying constraints including for example, supplied power, required performance, accuracy levels, available bandwidth, and quality of output such as image reconstruction. The process of determining an optimal solution is defined in terms of multi-objective optimization using Pareto-optimal realizations.

Abstract translation: 动态可重构框架管理处理应用程序，以便满足时变约束以选择最佳硬件体系结构。 最优架构满足时变约束，包括例如所提供的功率，所需性能，精度水平，可用带宽以及诸如图像重建的输出质量。 确定最优解的过程是使用帕累托最优实现的多目标优化来定义的。

公开(公告)号：US20140113891A1

公开(公告)日：2014-04-24

申请号：US13864916

申请日：2013-04-17

Applicant: University of Maryland, Baltimore ,  STC.UNM

Inventor： Alan E. Tomkinson ,  Xi Chen ,  Barbara Dziegielewska ,  Alexander D. Mackerell ,  Shijun Zhong ,  Gerald M. Wilson

IPC: C07D407/12 ,  A61K31/4245 ,  C07D271/12 ,  A61K31/41 ,  C07D257/04 ,  A61K31/423 ,  C07D263/58 ,  A61K31/4184 ,  C07D235/28 ,  A61K31/404 ,  C07D209/30 ,  A61K31/428 ,  C07D277/74 ,  A61K31/4439 ,  C07D401/12 ,  A61K31/433 ,  C07D285/14 ,  A61K31/553 ,  C07D267/18 ,  A61K31/341 ,  A61K31/436 ,  A61K31/495 ,  A61K31/175 ,  A61K45/06

CPC classification number: A61K31/505 ,  A61K31/165 ,  A61K31/166 ,  A61K31/175 ,  A61K31/255 ,  A61K31/341 ,  A61K31/397 ,  A61K31/404 ,  A61K31/41 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/433 ,  A61K31/436 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/553 ,  A61K45/06 ,  A61N5/10 ,  C07D209/30 ,  C07D235/28 ,  C07D257/04 ,  C07D263/58 ,  C07D267/18 ,  C07D271/12 ,  C07D277/74 ,  C07D285/14 ,  C07D307/68 ,  C07D401/12 ,  C07D407/12 ,  C40B30/02 ,  G01N21/64 ,  G06F19/16 ,  G06F19/706

Abstract: Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.

Abstract translation: 使用抑制人DNA连接酶的化合物治疗癌症的方法。 使用抑制人DNA连接酶的化合物提供人DNA连接酶的反应机制的见解的方法，例如鉴定参与不同DNA修复途径的人DNA连接酶。 抑制人类DNA连接酶的化合物的筛选方法。

公开(公告)号：US20140107394A1

公开(公告)日：2014-04-17

申请号：US14107541

申请日：2013-12-16

Applicant: STC.UNM

Inventor： Shuang Luan ,  Nathan Swanson ,  Lijun Ma

IPC: A61N5/10

CPC classification number: A61N5/1031 ,  A61B34/10 ,  A61B90/10 ,  A61B2090/101 ,  A61N5/103 ,  A61N5/1042 ,  A61N5/1084

Abstract: The present invention is a method and system for developing a dynamic scheme for Gamma Knife radiosurgery based on the concept of “dose-painting” to take advantage of robotic patient positioning systems on the Gamma Knife C and Perfexion units. The spherical high dose volume created by the Gamma Knife unit will be viewed as a 3D spherical “paintbrush”, and treatment planning is reduced to finding the best route of this “paintbrush” to “paint” a 3D tumor volume. Under the dose-painting concept, Gamma Knife radiosurgery becomes dynamic, where the patient is moving continuously under the robotic positioning system.

Abstract translation: 本发明是基于“剂量绘画”的概念，利用伽玛刀C和Perfexion单元上的机器人患者定位系统开发伽玛刀放射外科手术的动态方案和系统。 由伽玛刀单元创建的球形高剂量体积将被视为3D球形“画笔”，并且减少治疗计划以找到该“画笔”最佳路线来“绘制”3D肿瘤体积。 在剂量绘画概念下，伽玛刀放射外科手术变得动态，病人在机器人定位系统下连续移动。

公开(公告)号：US20130345277A1

公开(公告)日：2013-12-26

申请号：US13867658

申请日：2013-04-22

Applicant: STC.UNM ,  Kansas University Center for Technology Commercialization, Inc.

Inventor： Angela Wandinger-Ness ,  Larry Sklar ,  Zurab Surviladze ,  Tudor Oprea ,  Laurie Hudson ,  Jeffrey Aube ,  Jennifer E. Golden ,  Chad E. Schroeder ,  Denise S. Simpson ,  Julica J. Noth

IPC: A61K31/415 ,  A61K45/06 ,  C07D231/06

CPC classification number: A61K31/407 ,  A61K31/403 ,  A61K31/415 ,  A61K45/06 ,  C07D231/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/573 ,  Y02A50/473 ,  Y02A50/486 ,  A61K2300/00

Abstract: The present invention relates to molecules which function as selective modulators of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including Chlamydia infections, E. coli infections, H. pylori infections and its secondary effects including gastric ulcers, Coxiella Brunetti (Q-fever) infections and Streptococcus pneumonia infections, fungal infections including Paracoccidiodes brasiliensis and Candida albicans and their secondary effects including lung edema. Additionally, compounds according to the present invention may be used to inhibit rejection in transplant patients (pursuant to transplantation), to promote immunosuppression, anti-inflammatory response and to mobilize stem cell (migration) in patients in need, among others.

Abstract translation: 本发明涉及用作小GTP酶的Ras同源（Rho）家族，特别是Cdc42GTP酶的选择性调节剂的分子及其用于治疗疾病的用途，例如癌症，包括转移性癌症，遗传和获得性疾病，其中激活 的Cdc42 GTPase起着关键的作用，如神经退行性疾病，类风湿关节炎，动脉粥样硬化，I型糖尿病，常染色体多囊肾病，囊性肾病，前期肾脏疾病，微生物感染，包括衣原体感染，大肠杆菌感染，幽门螺杆菌 感染及其次要作用包括胃溃疡，布氏梭菌（Qex fever）感染和肺炎链球菌感染，包括巴西隐孢子虫和白色念珠菌在内的真菌感染及其副作用，包括肺水肿。 此外，根据本发明的化合物可以用于抑制移植患者的排斥（根据移植），以促进免疫抑制，抗炎反应和在需要的患者中调动干细胞（迁移）等。

公开(公告)号：US20130323310A1

公开(公告)日：2013-12-05

申请号：US13866764

申请日：2013-04-19

Applicant: STC.UNM

Inventor： Hugh D. Smyth ,  Martin J. Donovan

IPC: A61K9/00

CPC classification number: A61K9/0073 ,  A61K9/0075 ,  A61K9/0078 ,  A61K9/1641 ,  A61K47/60 ,  A61K47/6949 ,  A61K48/00 ,  B82Y5/00 ,  Y10T428/2982

Abstract: Swellable particles for delivering a working agent to the pulmonary system comprise a plurality of biodegradable particles each formed from a polymer network, each of the plurality of biodegradable particles having a mass mean aerodynamic diameter not exceeding 5 μm, the particles being swellable by hydration to a size that is greater than 6 μm volume mean diameter, and a working agent entrapped in the polymer network of each of the plurality of biodegradable particles.

Abstract translation: 用于将工作剂递送到肺系统的可溶胀颗粒包括多个可生物降解的颗粒，每个由聚合物网络形成，所述多个可生物降解的颗粒中的每一个具有不超过5μm的质量平均空气动力学直径，所述颗粒可以通过水合膨胀至 尺寸大于6μm体积平均直径，以及包埋在多个生物可降解颗粒中的每一个的聚合物网络中的工作剂。

公开(公告)号：US20130216478A1

公开(公告)日：2013-08-22

申请号：US13854560

申请日：2013-04-01

Applicant: STC.UNM

Inventor： Jeffrey P. Norenberg ,  Richard S. Larson

IPC: C07F9/94 ,  C07F5/00 ,  A61K51/04

CPC classification number: C07F5/003 ,  A61K47/22 ,  A61K49/106 ,  A61K51/0474 ,  A61K51/0482 ,  A61K51/0485 ,  A61K51/0497 ,  C07F9/94

Abstract: The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

Abstract translation: 本发明涉及用于对癌症特别是白血病和非霍奇金淋巴瘤（NHL）进行成像的新型非侵入性诊断工具，其体内毒性最小。 本发明代表了目前依赖于组织活检以诊断这些癌症的本领域的明显进步。 该新型成像探针能够检测癌前细胞，以及它们在组织中的转移扩散。 这代表了使用非侵入性分子成像技术在NHL的诊断和分期中向前推进的量子进程。 该新型探针也可用于监测患者对化疗治疗的反应和用于治疗NHL的其他干预措施或疗法。 根据本发明的化合物可以用作许多病症和疾病状态的诊断工具以及用于治疗这些病症和疾病状态的治疗剂。

公开(公告)号：US20130175501A1

公开(公告)日：2013-07-11

申请号：US13783219

申请日：2013-03-01

Applicant: STC.UNM

Inventor： Stephen D. Hersee ,  Xin Wang ,  Xinyu Sun

IPC: H01L21/02 ,  H01L29/20 ,  H01L29/04

CPC classification number: H01L29/413 ,  B82Y10/00 ,  B82Y20/00 ,  B82Y30/00 ,  C30B29/60 ,  H01L21/0237 ,  H01L21/02458 ,  H01L21/0254 ,  H01L21/02573 ,  H01L21/02603 ,  H01L21/02609 ,  H01L21/02612 ,  H01L21/0262 ,  H01L21/02636 ,  H01L21/02639 ,  H01L21/02642 ,  H01L29/045 ,  H01L29/0676 ,  H01L29/2003 ,  H01L29/775 ,  H01L31/0304 ,  H01L31/035236 ,  H01L31/184 ,  H01L33/18 ,  H01L33/24 ,  H01L2221/1094 ,  H01L2924/0002 ,  H01S5/1042 ,  H01S5/1835 ,  H01S5/18369 ,  H01S5/3428 ,  Y02E10/544 ,  Y02P70/521 ,  Y10S977/762 ,  Y10S977/816 ,  Y10T428/24612 ,  H01L2924/00

Abstract: Exemplary embodiments provide semiconductor devices including high-quality (i.e., defect free) group III-N nanowires and uniform group III-N nanowire arrays as well as their scalable processes for manufacturing, where the position, orientation, cross-sectional features, length and the crystallinity of each nanowire can be precisely controlled. A pulsed growth mode can be used to fabricate the disclosed group III-N nanowires and/or nanowire arrays providing a uniform length of about 10 nm to about 1000 microns with constant cross-sectional features including an exemplary diameter of about 10-1000 nm. In addition, high-quality GaN substrate structures can be formed by coalescing the plurality of GaN nanowires and/or nanowire arrays to facilitate the fabrication of visible LEDs and lasers. Furthermore, core-shell nanowire/MQW active structures can be formed by a core-shell growth on the nonpolar sidewalls of each nanowire.

Abstract translation: 示例性实施例提供包括高质量（即，无缺陷）III-N族纳米线和均匀III-N纳米线阵列的半导体器件及其可制造的可扩展工艺，其中位置，取向，横截面特征，长度和 可以精确地控制每个纳米线的结晶度。 可以使用脉冲生长模式来制造公开的提供约10nm至约1000微米的均匀长度的III-N族纳米线和/或纳米线阵列，其具有恒定的横截面特征，包括约10-1000nm的示例性直径。 此外，可以通过聚结多个GaN纳米线和/或纳米线阵列来形成高质量的GaN衬底结构，以便制造可见的LED和激光器。 此外，核 - 壳纳米线/ MQW活性结构可以通过在每个纳米线的非极性侧壁上的核 - 壳生长形成。

公开(公告)号：US20130146995A1

公开(公告)日：2013-06-13

申请号：US13764558

申请日：2013-02-11

Applicant: STC.UNM

Inventor： Jingkuang Chen

IPC: B06B1/06

CPC classification number: B06B1/06 ,  A61B1/041 ,  A61B8/12 ,  A61B8/4472 ,  A61B8/4488 ,  A61B8/4494 ,  B06B1/0292 ,  B81B2201/0271 ,  B81C1/00095 ,  B81C3/008 ,  G01S15/8929 ,  Y10T29/42

Abstract: Systems, apparatus, and associated methods of forming the systems and/or apparatus may include imaging devices that may comprise multiple arrays of ultrasonic transducer elements for use in a variety of applications. These multiple arrays of ultrasonic transducer elements can be arranged to form a three-dimensional imaging device. Non-coplanar arrays of ultrasonic transducer elements can be coupled together. These imaging devices may be used as medical imaging devices. Additional apparatus, systems, and methods are disclosed.

Abstract translation: 形成系统和/或装置的系统，装置和相关联的方法可以包括可以包括用于各种应用的超声换能器元件的多个阵列的成像装置。 这些多个超声波换能器阵列阵列可被布置成形成三维成像装置。 非共面阵列的超声换能器元件可以耦合在一起。 这些成像装置可以用作医疗成像装置。 公开了附加装置，系统和方法。